{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:52:06Z","timestamp":1790949126093,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82001897"],"award-info":[{"award-number":["82001897"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We aimed to construct and validate a radiomics prediction model based on preoperative T2-weighted MRI for prognosis and chemosensitivity prediction in patients with glioma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 576 glioma patients were enrolled in this study. The training and validation group included 324 patients and 127 patients respectively with preoperative MRI image data, tumor transcriptome sequencing data and clinical information. The prospective validation group consisted of 125 patients with preoperative MRI image data and clinical information. The radiomics prediction model was constructed based on the prognostic relevant radiomic features of glioma patients in the training group. The radiomics prediction model was validated inpatients of retrospective and prospective validation groups. Functional annotation of radiomic features was performed by pearson correlation analysis of biological process scores and radiomic features values of patients in the training group and validated by transcriptome sequencing, single cell sequencing, reactive oxygen species detection and endoplasmic reticulum stress detection of tumors of patients in retrospective and prospective validation groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The radiomics prediction model, which consisted of 17 radiomic features, showed highly predictive stability in overall survival and progression-free survival prediction. Compared with patients who underwent postoperative radiotherapy alone, only patients in the high-risk group benefited from postoperative chemoradiotherapy. The prognostic relevant radiomic features were closely related to immune response, reactive oxygen species metabolism and endoplasmic reticulum stress of glioma cells in silico and in vitro.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The radiomics prediction model serves as a non-invasive tool to predict prognosis and temozolomide chemosensitivity of glioma patients based on preoperative T2-weighted MRI.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-15726-8","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T23:35:01Z","timestamp":1771284901000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Radiomics of T2-weighted MRI for pretreatment prediction of prognosis and temozolomide chemosensitivity in glioma"],"prefix":"10.1186","volume":"26","author":[{"given":"Chongshun","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoyu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaopeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinli","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongliang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zenghui","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"issue":"2","key":"15726_CR1","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.canlet.2016.01.024","volume":"375","author":"T Jiang","year":"2016","unstructured":"Jiang T, Mao Y, Ma W, Mao Q, You Y, Yang X, et al. CGCG clinical practice guidelines for the management of adult diffuse gliomas. Cancer Lett. 2016;375(2):263\u201373.","journal-title":"Cancer Lett"},{"issue":"10","key":"15726_CR2","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant Temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987\u201396.","journal-title":"N Engl J Med"},{"issue":"1","key":"15726_CR3","first-page":"81","volume":"16","author":"J Beiko","year":"2014","unstructured":"Beiko J, Suki D, Hess KR, Fox BD, Cheung V, Cabral M, et al. IDH1 mutant malignant Astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neurooncology. 2014;16(1):81\u201391.","journal-title":"Neurooncology"},{"issue":"10","key":"15726_CR4","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene Silencing and benefit from Temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997\u20131003.","journal-title":"N Engl J Med"},{"issue":"1","key":"15726_CR5","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/s41467-019-08718-9","volume":"10","author":"H Lu","year":"2019","unstructured":"Lu H, Arshad M, Thornton A, Avesani G, Cunnea P, Curry E, et al. A mathematical-descriptor of tumor-mesoscopic-structure from computed-tomography images annotates prognostic- and molecular-phenotypes of epithelial ovarian cancer. Nat Commun. 2019;10(1):764.","journal-title":"Nat Commun"},{"issue":"2","key":"15726_CR6","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/s41571-021-00560-7","volume":"19","author":"K Bera","year":"2022","unstructured":"Bera K, Braman N, Gupta A, Velcheti V, Madabhushi A. Predicting cancer outcomes with radiomics and artificial intelligence in radiology. Nat Rev Clin Oncol. 2022;19(2):132\u201346.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"15726_CR7","doi-asserted-by":"publisher","first-page":"488","DOI":"10.2967\/jnumed.118.222893","volume":"61","author":"ME Mayerhoefer","year":"2020","unstructured":"Mayerhoefer ME, Materka A, Langs G, H\u00e4ggstr\u00f6m I, Szczypi\u0144ski P, Gibbs P, et al. Introduction to radiomics. J Nucl Med. 2020;61(4):488\u201395.","journal-title":"J Nucl Med"},{"key":"15726_CR8","doi-asserted-by":"crossref","unstructured":"Xia T, Zhao B, Li B, Lei Y, Song Y, Wang Y, et al. MRI-Based radiomics and deep learning in biological characteristics and prognosis of hepatocellular carcinoma: opportunities and challenges. J Magn Reson Imaging. 2024;59(3):767\u201383.","DOI":"10.1002\/jmri.28982"},{"issue":"3","key":"15726_CR9","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.diii.2022.10.008","volume":"104","author":"C Xue","year":"2023","unstructured":"Xue C, Zhou Q, Xi H, Zhou J, Radiomics. A review of current applications and possibilities in the assessment of tumor microenvironment. Diagn Interv Imaging. 2023;104(3):113\u201322.","journal-title":"Diagn Interv Imaging"},{"key":"15726_CR10","doi-asserted-by":"crossref","unstructured":"Alizadeh M, Broomand Lomer N, Azami M, Khalafi M, Shobeiri P, Arab Bafrani M, et al. Radiomics: the new promise for differentiating Progression, Recurrence, Pseudoprogression, and radionecrosis in glioma and glioblastoma multiforme. Cancers (Basel). 2023;15(18):4429.","DOI":"10.3390\/cancers15184429"},{"issue":"5","key":"15726_CR11","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41416-021-01387-w","volume":"125","author":"G Singh","year":"2021","unstructured":"Singh G, Manjila S, Sakla N, True A, Wardeh AH, Beig N, et al. Radiomics and radiogenomics in gliomas: a contemporary update. Br J Cancer. 2021;125(5):641\u201357.","journal-title":"Br J Cancer"},{"issue":"21","key":"15726_CR12","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1158\/0008-5472.CAN-17-0339","volume":"77","author":"JJM van Griethuysen","year":"2017","unstructured":"van Griethuysen JJM, Fedorov A, Parmar C, Hosny A, Aucoin N, Narayan V, et al. Computational radiomics system to Decode the radiographic phenotype. Cancer Res. 2017;77(21):e104\u20137.","journal-title":"Cancer Res"},{"issue":"1","key":"15726_CR13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/stem.1224","volume":"31","author":"DJ Castro","year":"2013","unstructured":"Castro DJ, Maurer J, Hebbard L, Oshima RG. ROCK1 Inhibition promotes the self-renewal of a novel mouse mammary cancer stem cell. Stem Cells. 2013;31(1):12\u201322.","journal-title":"Stem Cells"},{"issue":"2","key":"15726_CR14","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1148\/radiol.211986","volume":"303","author":"J Shin","year":"2022","unstructured":"Shin J, Seo N, Baek SE, Son NH, Lim JS, Kim NK, et al. MRI radiomics model predicts pathologic complete response of rectal cancer following chemoradiotherapy. Radiology. 2022;303(2):351\u20138.","journal-title":"Radiology"},{"key":"15726_CR15","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.ebiom.2019.03.050","volume":"42","author":"LL Zhang","year":"2019","unstructured":"Zhang LL, Huang MY, Li Y, Liang JH, Gao TS, Deng B, et al. Pretreatment MRI radiomics analysis allows for reliable prediction of local recurrence in non-metastatic T4 nasopharyngeal carcinoma. EBioMedicine. 2019;42:270\u201380.","journal-title":"EBioMedicine"},{"key":"15726_CR16","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.nicl.2017.10.030","volume":"17","author":"Y Li","year":"2018","unstructured":"Li Y, Qian Z, Xu K, Wang K, Fan X, Li S, et al. MRI features predict p53 status in lower-grade gliomas via a machine-learning approach. Neuroimage Clin. 2018;17:306\u201311.","journal-title":"Neuroimage Clin"},{"issue":"2","key":"15726_CR17","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00062-014-0289-3","volume":"25","author":"A Gupta","year":"2015","unstructured":"Gupta A, Young RJ, Shah AD, Schweitzer AD, Graber JJ, Shi W, et al. Pretreatment dynamic susceptibility contrast MRI perfusion in glioblastoma: prediction of EGFR gene amplification. Clin Neuroradiol. 2015;25(2):143\u201350.","journal-title":"Clin Neuroradiol"},{"issue":"6","key":"15726_CR18","doi-asserted-by":"publisher","first-page":"e1434466","DOI":"10.1080\/2162402X.2018.1434466","volume":"7","author":"Z Qian","year":"2018","unstructured":"Qian Z, Li Y, Fan X, Zhang C, Wang Y, Jiang T, et al. Molecular and clinical characterization of IDH associated immune signature in lower-grade gliomas. Oncoimmunology. 2018;7(6):e1434466.","journal-title":"Oncoimmunology"},{"issue":"7","key":"15726_CR19","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1007\/s00330-017-5267-0","volume":"28","author":"Y Li","year":"2018","unstructured":"Li Y, Liu X, Qian Z, Sun Z, Xu K, Wang K, et al. Genotype prediction of ATRX mutation in lower-grade gliomas using an MRI radiomics signature. Eur Radiol. 2018;28(7):2960\u20138.","journal-title":"Eur Radiol"},{"issue":"2","key":"15726_CR20","doi-asserted-by":"publisher","first-page":"673","DOI":"10.18632\/aging.101769","volume":"11","author":"X Liu","year":"2019","unstructured":"Liu X, Li Y, Li S, Fan X, Sun Z, Yang Z, et al. IDH mutation-specific radiomic signature in lower-grade gliomas. Aging. 2019;11(2):673\u201396.","journal-title":"Aging"},{"key":"15726_CR21","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.nicl.2018.10.014","volume":"20","author":"X Liu","year":"2018","unstructured":"Liu X, Li Y, Qian Z, Sun Z, Xu K, Wang K, et al. A radiomic signature as a non-invasive predictor of progression-free survival in patients with lower-grade gliomas. Neuroimage Clin. 2018;20:1070\u20137.","journal-title":"Neuroimage Clin"},{"issue":"6","key":"15726_CR22","first-page":"862","volume":"19","author":"H Zhou","year":"2017","unstructured":"Zhou H, Vallieres M, Bai HX, Su C, Tang H, Oldridge D, et al. MRI features predict survival and molecular markers in diffuse lower-grade gliomas. Neurooncology. 2017;19(6):862\u201370.","journal-title":"Neurooncology"},{"issue":"3","key":"15726_CR23","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1093\/brain\/awab340","volume":"145","author":"G Li","year":"2022","unstructured":"Li G, Li L, Li Y, Qian Z, Wu F, He Y, et al. An MRI radiomics approach to predict survival and tumour-infiltrating macrophages in gliomas. Brain. 2022;145(3):1151\u201361.","journal-title":"Brain"},{"issue":"9","key":"15726_CR24","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/S1470-2045(18)30413-3","volume":"19","author":"R Sun","year":"2018","unstructured":"Sun R, Limkin EJ, Vakalopoulou M, Dercle L, Champiat S, Han SR, et al. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Lancet Oncol. 2018;19(9):1180\u201391.","journal-title":"Lancet Oncol"},{"key":"15726_CR25","doi-asserted-by":"crossref","unstructured":"Grossmann P, Stringfield O, El-Hachem N, Bui MM, Rios Velazquez E, Parmar C, et al. Defining the biological basis of radiomic phenotypes in lung cancer. Elife. 2017;6:e23421.","DOI":"10.7554\/eLife.23421"},{"issue":"8","key":"15726_CR26","doi-asserted-by":"publisher","first-page":"eaat7314","DOI":"10.1126\/sciadv.aat7314","volume":"4","author":"HM De Feyter","year":"2018","unstructured":"De Feyter HM, Behar KL, Corbin ZA, Fulbright RK, Brown PB, McIntyre S, et al. Deuterium metabolic imaging (DMI) for MRI-based 3D mapping of metabolism in vivo. Sci Adv. 2018;4(8):eaat7314.","journal-title":"Sci Adv"},{"issue":"10","key":"15726_CR27","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1038\/s41422-021-00528-3","volume":"31","author":"XN Zhang","year":"2021","unstructured":"Zhang XN, Yang KD, Chen C, He ZC, Wang QH, Feng H, et al. Pericytes augment glioblastoma cell resistance to Temozolomide through CCL5-CCR5 paracrine signaling. Cell Res. 2021;31(10):1072\u201387.","journal-title":"Cell Res"},{"issue":"52","key":"15726_CR28","doi-asserted-by":"publisher","first-page":"e2302280","DOI":"10.1002\/smll.202302280","volume":"19","author":"MS Lam","year":"2023","unstructured":"Lam MS, Aw JJ, Tan D, Vijayakumar R, Lim HYG, Yada S, et al. Unveiling the influence of tumor microenvironment and Spatial heterogeneity on Temozolomide resistance in glioblastoma using an advanced human in vitro model of the Blood-Brain barrier and glioblastoma. Small. 2023;19(52):e2302280.","journal-title":"Small"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15726-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15726-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15726-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:20:28Z","timestamp":1781634028000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15726-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15726"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15726-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"assertion":[{"value":"24 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The requirement for ethical approval was waived by the Institutional Review Board of Beijing Tiantan Hospital, Capital Medical University. All patients provided informed consent. The study was performed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"398"}}